Advertising

Moderna

MRNA-Q

NASDAQ:MRNA

349.32
20.82 (6.34%)
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
More at Wikipedia

Analysis and Opinions about MRNA-Q

Signal
Opinion
Expert
Chart
BUY
BUY
July 21, 2021
Their targeted cancer vaccines will dwarf their revenues from even Covid. These are really smart guys and they're making tons of money.
Show full opinionHide full opinion
Moderna (MRNA-Q)
July 21, 2021
Their targeted cancer vaccines will dwarf their revenues from even Covid. These are really smart guys and they're making tons of money.
Jim Cramer - Mad Money
Price
$321.110
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
June 29, 2021
(A Top Pick Apr 08/21, Up 76.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRN is progressing well. We now recommend trailing up the stop (from $134) to $175. If triggered, this would all but guarantee a net investment return of 31%, when considering our previous recommendation to cover 50% of the holding.
Show full opinionHide full opinion
Moderna (MRNA-Q)
June 29, 2021
(A Top Pick Apr 08/21, Up 76.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRN is progressing well. We now recommend trailing up the stop (from $134) to $175. If triggered, this would all but guarantee a net investment return of 31%, when considering our previous recommendation to cover 50% of the holding.
BUY
BUY
June 7, 2021

He prefers it to Novavax, despite Novavax's good run today, because Moderna can do a lot more with its formulation.

Show full opinionHide full opinion
Moderna (MRNA-Q)
June 7, 2021

He prefers it to Novavax, despite Novavax's good run today, because Moderna can do a lot more with its formulation.

Jim Cramer - Mad Money
Price
$221.255
Owned
Unknown
BUY
BUY
May 7, 2021

Novavax Novavax is not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Show full opinionHide full opinion
Moderna (MRNA-Q)
May 7, 2021

Novavax Novavax is not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Jim Cramer - Mad Money
Price
$163.140
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 27, 2021
(A Top Pick Apr 08/21, Up 31.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has achieved our $175 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop to $134, just above the original recommended entry level. This would all but guarantee a minimum investment return exceeding 15%.
Show full opinionHide full opinion
Moderna (MRNA-Q)
April 27, 2021
(A Top Pick Apr 08/21, Up 31.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has achieved our $175 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop to $134, just above the original recommended entry level. This would all but guarantee a minimum investment return exceeding 15%.
TOP PICK
TOP PICK
April 8, 2021
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
Show full opinionHide full opinion
Moderna (MRNA-Q)
April 8, 2021
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
BUY
BUY
March 15, 2021
A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
Show full opinionHide full opinion
Moderna (MRNA-Q)
March 15, 2021
A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
Jim Cramer - Mad Money
Price
$143.650
Owned
Unknown
DON'T BUY
DON'T BUY
January 18, 2021
The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.
Show full opinionHide full opinion
Moderna (MRNA-Q)
January 18, 2021
The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.
COMMENT
COMMENT
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Show full opinionHide full opinion
Moderna (MRNA-Q)
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Christine Poole
Price
$156.600
Owned
No
COMMENT
COMMENT
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

Show full opinionHide full opinion
Moderna (MRNA-Q)
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

Paul Harris, CFA
Price
$81.685
Owned
Unknown
COMMENT
COMMENT
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Show full opinionHide full opinion
Moderna (MRNA-Q)
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Editor
Price
$68.140
Owned
Unknown
TOP PICK
TOP PICK
May 11, 2020
There are general concerns that any pharma company can mass-supply its vaccine, but Moderna vows to begin its still-unapproved vaccine “as early as July.” Moderna is partnering with Swiss drugmaker, Lonza, to accelerate production on mRNA-1273, which was the first candidate to enter a phase 1 human trial back in March, though results are pending. A week ago, Moderna submitted an application to the FDA to start a phase 2 trial. The company says phase 3 could happen as soon as the fall. Moderna is developing mRNA-1273 with partner NIH (the National Institutes of Health). The federal NIH explains that the partners developed a candidate early, because they were already researching “related coronaviruses” together. Unlike JNJ and Pfizer, Moderna's sole focus is vaccines to battle infectious diseases. Unlike those peers, Moderna did not suffer much of a plunge during the March bottom, and is currently trading at highs around $50. It pays no dividend and has an EPS of -1.55x and revenue growth of -55.42%. While JNJ and Pfizer can thrive if they don't find the vaccine, Moderna would have more to lose and the most to gain for this breakthrough.
Show full opinionHide full opinion
Moderna (MRNA-Q)
May 11, 2020
There are general concerns that any pharma company can mass-supply its vaccine, but Moderna vows to begin its still-unapproved vaccine “as early as July.” Moderna is partnering with Swiss drugmaker, Lonza, to accelerate production on mRNA-1273, which was the first candidate to enter a phase 1 human trial back in March, though results are pending. A week ago, Moderna submitted an application to the FDA to start a phase 2 trial. The company says phase 3 could happen as soon as the fall. Moderna is developing mRNA-1273 with partner NIH (the National Institutes of Health). The federal NIH explains that the partners developed a candidate early, because they were already researching “related coronaviruses” together. Unlike JNJ and Pfizer, Moderna's sole focus is vaccines to battle infectious diseases. Unlike those peers, Moderna did not suffer much of a plunge during the March bottom, and is currently trading at highs around $50. It pays no dividend and has an EPS of -1.55x and revenue growth of -55.42%. While JNJ and Pfizer can thrive if they don't find the vaccine, Moderna would have more to lose and the most to gain for this breakthrough.
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

Moderna(MRNA-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 7

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 7 stock analysts published opinions about MRNA-Q. 6 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-07-21. Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

7 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2021-07-28, Moderna (MRNA-Q) stock closed at a price of $349.32.